国际病理科学与临床杂志Issue(1)：12-18,7.DOI:10.3978/j.issn.2095-6959.2016.01.003
精氨酸加压素受体阻断剂改善小鼠脑卒中后脑水肿和血脑屏障破坏
Arginine-vasopressin receptor blocker improve brain edema and blood-brain barrier disruption after stroke in mice
熊军 1潘春联1
作者信息
- 1. 武汉普仁医院神经内科，武汉 430014
- 折叠
摘要
Abstract
Objective: To investigate if the arginine-vasopressin (AVP) receptor blockers conivaptan and tolvaptan can prevent brain edema and blood-brain barrier (BBB) disruption in mice after stroke.Methods: C57BL/6 mice underwent the filament model of middle cerebral artery occlusion with reperfusion. Mice were treated with conivaptan, tolvaptan, or vehicle. Treatments were initiated immediately at reperfusion and administered IV (conivaptan) or orally (tolvaptan) for 48 hours. Physiological variables, neurological deifcit scores (NDS), plasma and urine sodium and osmolality were recorded. Brain water content (BWC) and evans blue (EB) extravasation index were evaluated at the end point.Results: Both conivaptan and tolvaptan produced aquaresis as indicated by changes in plasma and urine sodium levels. However plasma and urine osmolality was changed only by conivaptan. Unlike tolvaptan, conivaptan improved NDS and reduced BWC in the ipsilateral hemisphere: from 81.66%±0.43% (vehicle) to 78.28%±0.48% (conivaptan, 0.2 mg,P<0.05 vs. vehicle). Conivaptan also attenuated the EB extravasation from 1.22%±0.08% (vehicle) to 1.01%±0.02% (conivaptan, 0.2 mg,P<0.05).Conclusion: Continuous IV infusion with conivaptan for 48 hours atfer experimental stroke reduces brain edema, and BBB disruption. Conivaptan may potentially be used to prevent brain edema atfer stroke.关键词
精氨酸加压素受体阻断剂/脑卒中/小鼠Key words
arginine-vasopressin receptor blocker/stroke/mice引用本文复制引用
熊军,潘春联..精氨酸加压素受体阻断剂改善小鼠脑卒中后脑水肿和血脑屏障破坏[J].国际病理科学与临床杂志,2016,(1):12-18,7.
